CAI - NASDAQ

Caris Life Sciences, Inc.

CAI·NASDAQ

$15.48

-1.5%

HealthcareBiotechnology

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.38B

EPS-1.9000

P/E Ratio-8.15

Earnings Date06/03/2026

1.13B

Assets

227%

3Y+57.0%

5Y-61.0%

10Y-43.0%

548.36M

Total Liabilities

-81%

3Y-77.0%

5Y-75.0%

10Y-64.0%

577.31M

Total Equity

-123%

3Y-134.0%

5Y-17.0%

10Y-

Caris Life Sciences, Inc. Funding & Solvency Profile

CAI · NASDAQ

Current Assets

Cash & Cash Equivalents797.80M

Net Receivables112.14M

Inventory0.00

Other Current Assets85.57M

Total Current Assets998 M

Non-Current Assets

Property, Plant & Equipment63.17M

Goodwill & Intangible Assets19.34M

Long-Term Investments0.00

Other Non-Current Assets45.35M

Total Non-Current Assets109 M

Total Assets

1.13B

Financial Health Analysis

Current Ratio

7.85x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.95x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

871 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

89% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Caris Life Sciences, Inc. Balance Sheet

CAI • NASDAQ

Caris Life Sciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006	Dec 2005
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	797.8M	64M	56.4M	107.2M	53.5M	46.5M	45.3M	35.4M	46.1M	52.6M	53.8M	45.7M	17.7M	14.1M	14.4M	14.5M	28.5M	8.4M	20.4M	7.6M
Short-Term Investments	2.3M	2.2M	65.2M	302.4M	79M	0.0	76M	30.1M	20M	21.2M	18.2M	13M	10.6M	6.2M	3.9M	6.8M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	800.1M	66.2M	121.6M	409.6M	132.5M	46.5M	121.3M	65.5M	66.1M	73.7M	72M	58.7M	28.3M	20.2M	18.3M	21.3M	28.5M	8.4M	20.4M	7.6M
Net Receivables	112.1M	88.2M	55.3M	40.2M	144.3M	159.7M	171.9M	100.7M	83.7M	76.4M	76.2M	64.9M	62.4M	45.4M	40.4M	33.4M	40.9M	35.2M	31.9M	27.5M
Accounts Receivables	112.1M	83.6M	48.7M	40.2M	144.3M	159.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	4.6M	6.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	39.6M	49M	47M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	13.6M	11.8M	13.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	85.6M	8.2M	5M	5.9M	-62.2M	293M	-73.2M	-25.8M	-14.6M	-6M	-3.3M	7.4M	4.4M	9.2M	9.9M	8.7M	11.5M	9.8M	7.2M	6.4M
Total Current Assets	997.8M	215.7M	242.6M	516M	214.7M	499.1M	220M	140.3M	135.2M	144.1M	144.8M	131M	95.1M	74.9M	68.7M	63.4M	81M	53.4M	59.5M	41.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	63.2M	102.8M	147.5M	138M	1.8B	1.8B	2.3B	2B	1.8B	1.7B	1.6B	1.5B	1.2B	843.9M	533.3M	299.8M	311M	243.1M	161.8M	437K
Goodwill	19.3M	19.3M	19.3M	19.3M	0.0	15.8M	15.8M	15.8M	15.8M	2.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.2M	50.2M	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	4.1M	5.7M	7.7M	9.7M	1.2M	273K	677K	1.4M	2.3M	3.6M	5.1M	6.6M	6M	7.1M	0.0
Goodwill & Intangible Assets	19.3M	19.3M	19.3M	19.3M	0.0	19.9M	21.5M	23.5M	25.5M	4.1M	273K	677K	1.4M	2.3M	3.6M	5.1M	6.6M	56.2M	57.3M	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	495.5M	473.8M	246.5M	80.6M	82.2M	76.8M	68.2M	74.9M	31.6M	7.9M	5.8M	14M	6M	4M	0.0
Other Non-Current Assets	45.3M	5.9M	3.4M	44M	616.6M	66.5M	31.1M	14.8M	7.2M	7.2M	8.2M	9.3M	4.4M	599K	0.0	0.0	0.0	356K	329K	138.8M
Total Non-Current Assets	127.9M	128M	170.3M	201.4M	2.4B	2.4B	2.8B	2.3B	1.9B	1.8B	1.7B	1.5B	1.3B	878.5M	544.8M	310.7M	331.6M	305.7M	223.5M	139.3M
Total Assets	1.1B	343.7M	412.9M	717.4M	2.6B	2.9B	3B	2.4B	2.1B	2B	1.8B	1.7B	1.4B	953.4M	613.5M	374.1M	412.6M	359.1M	283M	180.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	39.2M	27.8M	26.7M	27.3M	3.7M	7.3M	7.4M	7.8M	13.8M	12M	8.4M	8M	6M	3.5M	2.4M	8M	4.7M	3.1M	3.6M	3.5M
Accounts Payable	39.2M	27.8M	26.7M	27.3M	3.7M	7.3M	7.4M	7.8M	13.8M	12M	8.4M	8M	6M	3.5M	2.4M	8M	4.7M	3.1M	3.6M	3.5M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	-7.4M	-7.8M	-13.8M	-12M	-8.4M	-8M	-6M	-3.5M	-2.4M	-8M	-4.7M	-3.1M	-3.6M	-3.5M
Accrued Expenses	0.0	33.3M	33.9M	28.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	169K	60M	167K	52.8M	183.4M	218.1M	311.4M	132M	95.5M	172.4M	204.2M	76M	63.3M	29.6M	29.2M	4.6M	4.5M	31K	5.5M	703K
Capital Lease Obligations (Current)	0.0	6.2M	6.6M	4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	7.5M	5.7M	1.4M	3M	6.4M	7.6M	7.8M	10.6M	12M	7.2M	6.9M	7.9M	6.8M	5.7M	4.2M	4.5M	3.7M	740K	0.0
Other Current Liabilities	87.8M	30.7M	22.1M	22.7M	130.1M	55.6M	99.2M	112.2M	44.1M	21.5M	29.4M	66.1M	29.6M	39.2M	116.8M	21.6M	31.5M	49.8M	67.7M	40.7M
Total Current Liabilities	127.1M	165.4M	95.1M	136.9M	320.3M	287.4M	425.5M	259.9M	164M	217.9M	249.2M	156.9M	106.8M	79.1M	154.2M	38.5M	45.2M	56.6M	77.6M	45M
NON-CURRENT LIABILITIES
Long Term Debt	378.8M	319.2M	166.1M	169.6M	1.6B	1.9B	1.8B	1.6B	1.4B	1.3B	1.1B	1.1B	889M	524M	220.8M	163.6M	208.2M	147.6M	148.3M	64M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	24.4M	35.4M	38.3M	35.9M	51.8M	48.2M	43.4M	41.4M	40.1M	33.8M	30.2M	26.6M	25.3M	23.7M	24.5M	22.1M
Other Non-Current Liabilities	42.4M	2.3B	2.3B	2.1B	3.4M	5.6M	0.0	0.0	2.1M	0.0	1.6M	3.5M	5.3M	67.7M	10.6M	16.3M	20.1M	0.0	4.9M	16.6M
Total Non-Current Liabilities	421.2M	2.7B	2.5B	2.3B	1.6B	1.9B	1.9B	1.6B	1.4B	1.3B	1.1B	1.1B	934.3M	625.6M	261.6M	206.5M	253.6M	171.3M	177.7M	102.7M
Capital Lease Obligations	0.0	45.1M	51M	48.5M	0.0	0.0	67.6M	69.4M	71.3M	53.7M	67.8M	106.6M	82.5M	20.3M	14.9M	20.1M	22.6M	80K	556K	886K
Total Liabilities	548.4M	2.8B	2.6B	2.4B	1.9B	2.2B	2.3B	1.9B	1.6B	1.5B	1.4B	1.3B	1B	704.6M	415.8M	245M	298.8M	228M	255.2M	147.7M
SHAREHOLDERS' EQUITY
Treasury Stock	-16.9M	-330K	-330K	-330K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	103.9M	103.9M	103.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9M	6.4M
Common Stock	283K	38K	38K	138K	2K	2K	2K	2K	2K	2K	2K	2K	2K	2K	2K	2K	2K	2K	1.3M	2.5M
Additional Paid-In Capital	3.1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-2.5B	-2.5B	-2.1B	-1.7B	503.3M	493.3M	471.1M	397.6M	324.6M	319.7M	292.9M	232.6M	168.7M	105.2M	55M	26.7M	13.1M	40.1M	26.4M	30.5M
Accumulated Other Comprehensive Income/Loss	936K	210K	218K	1.7M	-5.7M	-6.6M	-6.5M	-6.1M	-8.1M	-7.9M	-5.7M	-2.4M	-2.9M	-3.4M	-2.5M	-1.2M	-2M	101K	95K	-44K
Other Total Stockholders' Equity	0.0	-26.5M	-25.7M	-25M	100.8M	102.7M	132.7M	172.3M	141.1M	148.5M	154.9M	184.3M	181.1M	128.2M	127.1M	103.7M	102.7M	91M	-4.9M	-6.4M
Total Stockholders' Equity	577.3M	-2.5B	-2.1B	-1.7B	702.2M	693.2M	701.1M	563.8M	457.5M	460.3M	442.1M	414.5M	346.8M	230M	179.6M	129.1M	113.8M	131.1M	27.8M	33M
Total Equity	577.3M	-2.5B	-2.1B	-1.7B	702.2M	693.2M	701.1M	563.8M	457.5M	0.0	0.0	0.0	346.8M	0.0	0.0	129.1M	113.8M	131.1M	27.8M	33M
SUMMARY
Total Liabilities & Equity	1.1B	343.7M	412.9M	717.4M	2.6B	2.9B	3B	2.4B	2.1B	2B	1.8B	1.7B	1.4B	934.7M	595.4M	374.1M	412.6M	359.1M	283M	180.7M
Total Investments	2.3M	2.2M	65.2M	302.4M	79M	495.5M	549.8M	276.5M	100.5M	103.4M	95M	81.2M	85.6M	37.7M	11.8M	12.6M	14M	6M	4M	0.0
Total Debt	379M	424.3M	217.3M	270.9M	1.7B	2.1B	2.2B	1.7B	1.5B	1.4B	1.3B	1.1B	952.3M	553.6M	250M	168.3M	212.7M	147.6M	153.8M	64.7M
Net Debt	-418.8M	360.3M	160.9M	163.7M	1.7B	2.1B	2.1B	1.7B	1.4B	1.4B	1.2B	1.1B	934.6M	539.5M	235.6M	153.8M	184.2M	139.2M	133.4M	57.1M
Shares Outstanding	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923	282,146,923

SEC Filings

CAI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	April 01, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 30, 2025	2025	View Filing

Showing 1 to 10 of 16 filings

Related Guides

Blog Categories

Continue your CAI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.